Status:

COMPLETED

Fibromyalgia Study In Adults

Lead Sponsor:

GlaxoSmithKline

Conditions:

Fibromyalgia Syndrome, Primary

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

A study to investigate ropinirole for treatment of the symptoms of fibromyalgia and in particular the widespread pain associated with this condition. A total 160 subjects (80 per treatment arm) are be...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Diagnosis of primary fibromyalgia as defined by the American College of Rheumatology (ACR).
  • Females of childbearing potential will only be eligible if taking adequate contraceptive measures.
  • Other co-existent chronic pain conditions such as osteoarthritis, will not exclude the subject if the pain associated with the condition is less severe than the pain of fibromyalgia.
  • Only subjects experiencing moderate/severe pain (pain intensity score \>= 4 on the pain numerical rating scale) will be eligible for this study.
  • Subjects that are generally well.
  • Have the ability to discontinue prohibited medications for the duration of the study.
  • Exclusion criteria:
  • Subjects with 'flare' of arthritic conditions.
  • Evidence of clinically significant medical conditions including cardiovascular conditions (e.g. postural hypotension, and raised blood pressure, ECG abnormalities).
  • History of drug and/or alcohol abuse or major depression.

Exclusion

    Key Trial Info

    Start Date :

    November 1 2004

    Trial Type :

    INTERVENTIONAL

    End Date :

    July 1 2005

    Estimated Enrollment :

    164 Patients enrolled

    Trial Details

    Trial ID

    NCT00256893

    Start Date

    November 1 2004

    End Date

    July 1 2005

    Last Update

    September 15 2016

    Active Locations (22)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 6 (22 locations)

    1

    GSK Investigational Site

    Brussels, Belgium, 1070

    2

    GSK Investigational Site

    Diepenbeek, Belgium, 3590

    3

    GSK Investigational Site

    Merksem, Belgium, 2170

    4

    GSK Investigational Site

    Frederiksberg, Denmark, 2000